Harvard Bioscience misses audit committee independence; Nasdaq confirms; cure period through June 2026

HARVARD BIOSCIENCE INC

Alan Edrick resigned from Board and Audit Committee effective June 10, 2025, leaving only two audit committee members.
Nasdaq Staff notified Company on June 26, 2025 that it no longer meets Audit Committee Composition Requirement (Rule 5605(c)(2)(A)).
Company has cure period until earlier of next annual meeting or June 10, 2026 to fill vacancy with independent director.
Company intends to appoint a new independent Board member expeditiously to regain compliance.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.